
Allogene gains 17 assets from Pfizer
Executive Summary
Newly launched with $300mm in Series A backing, Allogene Therapeutics Inc. is acquiring from Pfizer Inc. assets that the Big Pharma licensed from Cellectis SA in 2014 and Servier SA in 2015.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com